ANGPTL7產(chǎn)品信息
別稱:ANGPTL7,CDT6
物種:Human
屬性:Protein
標(biāo)記:Biotin-labeled/Unconjugated
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
ANGPTL7分子背景
促血管生成素樣7(ANGPTL7)也被稱為角膜衍生轉(zhuǎn)錄物6(CDT6),是一種分泌的糖蛋白,在結(jié)構(gòu)上與促血管生成蛋白有關(guān)。它在角膜基質(zhì)、小梁網(wǎng)和鞏膜中表達(dá),在青光眼房水中升高。最近,ANGPTL蛋白,包括ANGPTL-2、-3、-4、-5和-7,被鑒定為與SCF、血小板生成素、IGF-II和FGF酸性結(jié)合的生長因子,可增強(qiáng)人和小鼠造血干細(xì)胞的擴(kuò)增和植入。
關(guān)鍵字: ANGPTL7;ANGPTL7蛋白;CDT6蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。